Author + information
- Received June 8, 2004
- Revision received August 10, 2004
- Accepted August 23, 2004
- Published online September 20, 2005.
- Peter J. Mason, MD, MPH⁎ (, )
- Alice K. Jacobs, MD, FACC and
- Jane E. Freedman, MD, FACC
- ↵⁎Reprint requests and correspondence:
Dr. Peter J. Mason, Brigham and Women’s Hospital, Division of Cardiovascular Medicine, 75 Francis Street, Boston, Massachusetts 02115.
Acute coronary syndromes and other manifestations of atherothrombotic disease are primarily caused by atherosclerotic plaque rupture or fissuring and subsequent occlusive or subocclusive thrombus formation. Platelets play a critical role in the pathophysiology of atherothrombotic disease, and aspirin is the most commonly used antiplatelet agent. Clinical trials have demonstrated the efficacy of aspirin in both primary and secondary prevention of myocardial infarction, stroke, and cardiovascular death. Despite its proven benefit, the absolute risk of recurrent vascular events among patients taking aspirin remains relatively high, an estimated 8% to 18% after two years. Therapeutic resistance to aspirin might explain a portion of this risk. Although formal diagnostic criteria and a validated method of measurement are lacking, aspirin resistance may affect between 5% and 45% of the population. Given the prevalence of cardiovascular disease, the potential impact of aspirin resistance is large. Currently, however, there are many unanswered questions regarding the biological mechanism, diagnosis, population prevalence, clinical relevance, and optimal therapeutic intervention for aspirin resistance.
- Received June 8, 2004.
- Revision received August 10, 2004.
- Accepted August 23, 2004.
- American College of Cardiology Foundation